CA2521391A1 - Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate - Google Patents

Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate Download PDF

Info

Publication number
CA2521391A1
CA2521391A1 CA002521391A CA2521391A CA2521391A1 CA 2521391 A1 CA2521391 A1 CA 2521391A1 CA 002521391 A CA002521391 A CA 002521391A CA 2521391 A CA2521391 A CA 2521391A CA 2521391 A1 CA2521391 A1 CA 2521391A1
Authority
CA
Canada
Prior art keywords
omeprazole
preparation
salt
trihydrate
potassium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002521391A
Other languages
French (fr)
Other versions
CA2521391C (en
Inventor
Hanna Cotton
Anders Kronstroem
Anders Mattson
Eva Moeller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astrazeneca Ab
Hanna Cotton
Anders Kronstroem
Anders Mattson
Eva Moeller
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2521391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Hanna Cotton, Anders Kronstroem, Anders Mattson, Eva Moeller, Astra Aktiebolag filed Critical Astrazeneca Ab
Publication of CA2521391A1 publication Critical patent/CA2521391A1/en
Application granted granted Critical
Publication of CA2521391C publication Critical patent/CA2521391C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

As an intermediate for the preparation of the magnesium salt of S-omeprazole trihydrate there is provided a potassium salt of S-omeprazole and a process for preparation thereof.
CA002521391A 1997-05-30 1998-05-25 Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate Expired - Lifetime CA2521391C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702065A SE510650C2 (en) 1997-05-30 1997-05-30 New association
SE9702065-5 1997-05-30
CA002290963A CA2290963C (en) 1997-05-30 1998-05-25 S-omeprazole magnesium trihydrate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002290963A Division CA2290963C (en) 1997-05-30 1998-05-25 S-omeprazole magnesium trihydrate

Publications (2)

Publication Number Publication Date
CA2521391A1 true CA2521391A1 (en) 1998-12-03
CA2521391C CA2521391C (en) 2009-09-29

Family

ID=20407186

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002290963A Expired - Lifetime CA2290963C (en) 1997-05-30 1998-05-25 S-omeprazole magnesium trihydrate
CA002521391A Expired - Lifetime CA2521391C (en) 1997-05-30 1998-05-25 Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002290963A Expired - Lifetime CA2290963C (en) 1997-05-30 1998-05-25 S-omeprazole magnesium trihydrate

Country Status (44)

Country Link
US (6) US6369085B1 (en)
EP (2) EP0984957B3 (en)
JP (2) JP4002303B2 (en)
KR (2) KR100540720B1 (en)
CN (1) CN1161351C (en)
AR (2) AR012717A1 (en)
AT (2) ATE239011T1 (en)
AU (1) AU722839B2 (en)
BR (1) BR9809509A (en)
CA (2) CA2290963C (en)
CY (1) CY2012029I2 (en)
CZ (1) CZ297585B6 (en)
DE (3) DE69814069T3 (en)
DK (2) DK0984957T3 (en)
DZ (1) DZ2495A1 (en)
EE (1) EE03875B1 (en)
EG (1) EG24291A (en)
ES (2) ES2195345T7 (en)
HK (2) HK1025962A1 (en)
HR (1) HRP980263B1 (en)
HU (1) HU225987B1 (en)
ID (1) ID29306A (en)
IL (1) IL132947A0 (en)
IS (2) IS2142B (en)
LU (2) LU91871I2 (en)
MA (1) MA26500A1 (en)
ME (3) MEP24908A (en)
MY (2) MY120745A (en)
NO (3) NO317518B1 (en)
NZ (1) NZ500991A (en)
PL (1) PL193546B1 (en)
PT (2) PT984957E (en)
RS (2) RS50067B (en)
RU (1) RU2184115C2 (en)
SA (2) SA05260296B1 (en)
SE (1) SE510650C2 (en)
SI (2) SI1273581T1 (en)
SK (2) SK284837B6 (en)
TN (1) TNSN98074A1 (en)
TR (1) TR199902934T2 (en)
TW (1) TW538040B (en)
UA (1) UA60334C2 (en)
WO (1) WO1998054171A1 (en)
ZA (1) ZA984179B (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (en) * 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE69737413T2 (en) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville BACTERIOFERRITINE FROM HELICOBACTER PYLORI
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE510650C2 (en) 1997-05-30 1999-06-14 Astra Ab New association
SE9900274D0 (en) * 1999-01-28 1999-01-28 Astra Ab New compound
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
PT1487818E (en) 2002-03-05 2007-07-18 Astrazeneca Ab Alkylammonium salts of omeprazole and esomeprazole
AU2003262375A1 (en) * 2002-04-22 2003-11-03 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
EP1515963B1 (en) * 2002-06-27 2007-02-14 Dr. Reddy's Laboratories Ltd. A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
CN100378093C (en) * 2002-06-27 2008-04-02 雷迪实验室有限公司 Method for preparing optical purity or optically concentrated sulfoxide compounds comprising amorphous esomeprazole and its salts
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
AU2003262992A1 (en) * 2002-08-30 2004-03-19 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
CA2502219C (en) * 2002-10-16 2012-05-29 Takeda Pharmaceutical Company Limited A process for producing an amorphous isomer of lansoprazole
US20040235903A1 (en) * 2002-10-22 2004-11-25 Khanna Mahavir Singh Amorphous form of esomeprazole salts
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
US20060094762A1 (en) * 2003-01-07 2006-05-04 Yatendra Kumar Magnesium salt of imidazole derivative
AU2003238671A1 (en) * 2003-04-10 2004-11-01 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
WO2004099181A1 (en) 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SI1651217T1 (en) * 2003-07-23 2008-08-31 Nycomed Gmbh Alkaline salts of proton pump inhibitors
CN100457104C (en) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 Alkaline salts of proton pump inhibitors
SE0302381D0 (en) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (en) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007523163A (en) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド Methods and compositions for the administration of prodrugs of proton pump inhibitors
BRPI0507837A (en) * 2004-02-18 2007-07-10 Allergan Inc methods and compositions for intravenous administration of compounds related to proton pump inhibitors
WO2005117870A2 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
JP5457632B2 (en) * 2004-06-24 2014-04-02 アストラゼネカ・アクチエボラーグ Process for making modified forms of crystals for use in the manufacture of sodium salt of esomeprazole
ES2246149B1 (en) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. SOLID FORMS OF S-OMEPRAZOL MAGNETIC SALT AND PROCEDURES FOR PREPARATION.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (en) 2005-03-03 2007-11-01 Esteve Quimica, S.A. PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 2- (2-PIRIDILMETILSULFINIL) -BENCIMIDAZOL OPTICALLY ACTIVE.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
RU2007145207A (en) * 2005-05-06 2009-06-20 Гленмарк Фармасьютикалз Лимитед (In) ESOMEPRAZOL STRONGTED SALT, METHOD FOR PRODUCING IT AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS
WO2006134605A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr Omeprazole form b
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
KR100641534B1 (en) 2005-07-28 2006-11-01 한미약품 주식회사 Process of esomeprazole and salts thereof
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
JP2009511481A (en) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド Gastric H +, K + -ATPase deuteration inhibitors with enhanced therapeutic properties
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
RU2372345C1 (en) * 2005-10-26 2009-11-10 Ханми Фарм. Ко., Лтд. S-omeprazole strontium salt or hydrate thereof, method of preparing said compounds and pharmaceutical composition containing said compounds
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (en) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 Prepn process of [(substituted pyridyl) methyl] sulfenyl-1H-benzimidazole compound and its antimer zinc salt
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US20100286208A1 (en) * 2006-06-21 2010-11-11 Bobba Venkata Siva Kumar Novel polymorph of esomeprazole potassium and process for its preparation
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EP1947099A1 (en) * 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
EA200900985A1 (en) 2007-01-31 2009-12-30 Крка, Товарна Здравил, Д. Д., Ново Место METHOD OF OBTAINING OPTICAL PURE OMEPRAZOL
KR101522865B1 (en) * 2007-02-21 2015-05-26 시플라 리미티드 Process for the preparation of form a of esomeprazole magnesium dihydrate
KR101303813B1 (en) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 Improved preparing method of (S)-omeprazole from omeprazole racemate using optical resolution agent
EP2000468A1 (en) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
EP2152691B1 (en) * 2007-06-07 2011-11-23 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
FR2920428B1 (en) * 2007-08-29 2012-06-15 Univ Rouen PROCESS FOR DEDOLDING SALTS OF OMEPRAZOLE
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
CN104069088A (en) 2007-10-12 2014-10-01 武田制药北美公司 Methods of treating gastrointestinal disorders independent of the intake of food
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2240496A4 (en) * 2008-02-01 2011-05-11 Reddys Lab Ltd Dr Preparation of esomeprazole magnesium and hydrates thereof
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) * 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
CN101391993B (en) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 Method for preparing S-omeprazole and salt thereof by forming inclusion complex with (S)-(-)-1,1'-dinaphthalene-2,2'-diol
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
US20130030186A1 (en) * 2009-06-02 2013-01-31 Sun Pharmaceutical Industries Limited Process for preparing sulphoxide compounds
EA201290026A1 (en) 2009-06-25 2012-07-30 Астразенека Аб A METHOD FOR TREATING A PATIENT THAT HAS A RISK OF DEVELOPMENT OF ANALISM ASSOCIATED WITH THE RECEPTION OF NONSTEROID ANTI-INFLAMMATORY MEDIA
KR20120093140A (en) * 2009-06-25 2012-08-22 포젠 인크. Method for treating a patient in need of aspirin therapy
WO2011012957A1 (en) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of esomeprazole magnesium dihydrate
EP2499125B1 (en) 2009-11-12 2016-01-27 Hetero Research Foundation Process for the resolution of omeprazole
SI2510089T1 (en) 2009-12-08 2015-12-31 Codexis, Inc. Synthesis of prazole compounds
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (en) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese PRECURSOR PHASE AND USE THEREOF FOR PREPARING MAGNESIUM TETRAHYDRATE SALT OF AN OMEPRAZOLE ENANTIOMER
CN102241668B (en) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 Esomprazole salt
WO2012078800A2 (en) 2010-12-08 2012-06-14 Codexis, Inc. Biocatalysts and methods for the synthesis of armodafinil
CN102757421A (en) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 Purification method of esomeprazole
CN104844577A (en) * 2011-07-31 2015-08-19 连云港润众制药有限公司 Crystal forms of esomeprazole magnesium
CN102924435B (en) * 2011-11-25 2014-06-25 成都自豪药业有限公司 Novel crystal form of S-omeprazole magnesium salt and preparing method thereof
WO2013088272A1 (en) * 2011-12-14 2013-06-20 Wockhardt Limited Pharmaceutical composition comprising esomeprazole magnesium dihydrate
CN104519888A (en) 2011-12-28 2015-04-15 波曾公司 Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102584792B (en) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 Method for preparing high-purity esomeprazole
CN102993184A (en) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 Esomeprazole and preparation method of magnesium trihydrate of esomeprazole
CN104250243B (en) * 2013-06-27 2016-12-28 四川国为制药有限公司 A kind of preparation method of Esomeprazole magnesium dihydrate A crystal formation
CN103570686B (en) * 2013-10-14 2015-04-01 哈药集团技术中心 Method for synthesizing and refining esomeprazole sodium
CN104725357A (en) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 Preparation method of esomeprazole magnesium dihydrate crystal form B
FR3018812A1 (en) * 2014-03-21 2015-09-25 Minakem NOVEL INTERMEDIATE PHASE OF FORM A OF MAGNESIUM SALT DIHYDRATE OF AN OMEPRAZOLE ENANTIOMER
CN104447699A (en) * 2014-12-10 2015-03-25 哈药集团技术中心 Preparation method of esomeprazole magnesium trihydrate
CN105111188B (en) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 A kind of preparation method of esomeprazole magnesium trihydrate crystal formation
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106397402B (en) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 A kind of esomeprazole magnesium crystal-form compound and preparation method thereof
KR102080023B1 (en) 2018-01-29 2020-02-21 주식회사 종근당 Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
KR102006777B1 (en) 2018-01-29 2019-10-08 주식회사 종근당 Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate
KR102432084B1 (en) 2021-11-16 2022-08-12 알리코제약(주) S-omeprazole tablet having improved stability and miniaturized size
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
SE8301182D0 (en) 1983-03-04 1983-03-04 Haessle Ab NOVEL COMPOUNDS
US5244891A (en) 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
DE4035455A1 (en) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab ENANTIOMER SEPARATION
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (en) 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
SE9302395D0 (en) * 1993-07-09 1993-07-09 Ab Astra NEW PHARMACEUTICAL FORMULATION
SE9302396D0 (en) * 1993-07-09 1993-07-09 Ab Astra A NOVEL COMPOUND FORM
FR2719045B1 (en) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Process for the preparation of L-aspartic acid from ammonium aspartate.
FR2722191B1 (en) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF (2R, 3S) -3-TERTBUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE (2R, 3S) TRIHYDRATE, 20EPOXY-11BYA -13ALPHA-YLE
ES2100142T3 (en) 1994-07-08 2002-03-01 Astrazeneca Ab DOSAGE FORM IN TABLETS I CONSTITUTED BY MULTIPLE UNITS.
SE504459C2 (en) 1994-07-15 1997-02-17 Astra Ab Process for the preparation of substituted sulfoxides
KR100372188B1 (en) 1994-11-14 2003-05-12 다이이찌 세이야꾸 가부시기가이샤 (3-chloro-2-methylphenyl) -1-pyrazazinyl] ethyl] -5,6-dimethoxy- 1- (4- imidazolylmethyl) Crystalline hydrochloride and method for producing the same
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (en) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (en) 1995-05-25 1999-03-10 常州市第四制药厂 Aomeilazole salt hydrate for gastric acid inhibitor and its preparing method
SE9600070D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE510650C2 (en) * 1997-05-30 1999-06-14 Astra Ab New association
US6747155B2 (en) * 1997-05-30 2004-06-08 Astrazeneca Ab Process
AR057181A1 (en) 2005-11-30 2007-11-21 Astra Ab NEW COMBINATION DOSAGE FORM

Also Published As

Publication number Publication date
EE03875B1 (en) 2002-10-15
DE69814069D1 (en) 2003-06-05
HK1051681A1 (en) 2003-08-15
WO1998054171A1 (en) 1998-12-03
HK1025962A1 (en) 2000-12-01
ES2195345T3 (en) 2003-12-01
AR012717A1 (en) 2000-11-08
MEP24908A (en) 2010-10-10
AU7793598A (en) 1998-12-30
RS50067B (en) 2009-01-22
HRP980263B1 (en) 2002-02-28
TW538040B (en) 2003-06-21
US20080255363A1 (en) 2008-10-16
US20050075369A1 (en) 2005-04-07
CA2290963C (en) 2006-03-28
LU92017I2 (en) 2012-08-06
EE9900550A (en) 2000-06-15
NO2011010I1 (en) 2011-06-20
ATE291574T1 (en) 2005-04-15
SI1273581T1 (en) 2005-08-31
SK285137B6 (en) 2006-07-07
SI0984957T1 (en) 2003-10-31
DE69829511T2 (en) 2006-02-16
DK0984957T3 (en) 2003-06-30
PT984957E (en) 2003-07-31
ME00198B (en) 2011-02-10
KR100540720B1 (en) 2006-01-12
HRP980263A2 (en) 1999-02-28
EP1273581B1 (en) 2005-03-23
DE69814069T2 (en) 2004-04-01
PT1273581E (en) 2005-06-30
CY2012029I1 (en) 2015-08-05
HUP0001849A3 (en) 2003-02-28
AR059589A2 (en) 2008-04-16
MY120745A (en) 2005-11-30
DE69814069T3 (en) 2014-03-27
IS8368A (en) 2006-03-22
NO995852D0 (en) 1999-11-29
RS20070459A (en) 2008-06-05
PL337180A1 (en) 2000-08-14
NO317518B1 (en) 2004-11-08
ZA984179B (en) 1998-11-30
KR20010013126A (en) 2001-02-26
DK1273581T3 (en) 2005-06-06
LU91871I2 (en) 2011-11-21
US20110130570A1 (en) 2011-06-02
CY2012029I2 (en) 2015-08-05
NZ500991A (en) 2001-05-25
KR20050042827A (en) 2005-05-10
SA98190280B1 (en) 2006-07-04
CA2290963A1 (en) 1998-12-03
US20120252847A1 (en) 2012-10-04
PL193546B1 (en) 2007-02-28
IS2774B (en) 2012-03-15
SE9702065D0 (en) 1997-05-30
WO1998054171A8 (en) 1999-12-23
JP2007161734A (en) 2007-06-28
IL132947A0 (en) 2001-03-19
SE9702065L (en) 1998-12-01
RU2184115C2 (en) 2002-06-27
TNSN98074A1 (en) 2005-03-15
MA26500A1 (en) 2004-12-20
ES2195345T7 (en) 2014-01-15
US7411070B2 (en) 2008-08-12
SE510650C2 (en) 1999-06-14
AU722839B2 (en) 2000-08-10
DZ2495A1 (en) 2003-01-25
NO2012011I1 (en) 2012-06-18
ID29306A (en) 2001-08-16
HU0001849D0 (en) 2002-05-29
IS5272A (en) 1999-11-25
US6677455B2 (en) 2004-01-13
EP0984957B1 (en) 2003-05-02
US8466175B2 (en) 2013-06-18
CA2521391C (en) 2009-09-29
MEP18008A (en) 2010-10-10
RS50005B (en) 2008-09-29
KR100527804B1 (en) 2005-11-15
US8076361B2 (en) 2011-12-13
SK284837B6 (en) 2005-12-01
CZ297585B6 (en) 2007-01-10
SK162599A3 (en) 2000-06-12
DE69829511D1 (en) 2005-04-28
CN1161351C (en) 2004-08-11
ES2236407T3 (en) 2005-07-16
BR9809509A (en) 2000-06-20
JP4002303B2 (en) 2007-10-31
DE122012000017I1 (en) 2012-08-16
EP0984957B3 (en) 2013-09-18
TR199902934T2 (en) 2000-04-21
SA05260296B1 (en) 2008-04-16
EP1273581A1 (en) 2003-01-08
US7745466B2 (en) 2010-06-29
US6369085B1 (en) 2002-04-09
IS2142B (en) 2006-09-15
EP0984957A1 (en) 2000-03-15
YU60999A (en) 2002-03-18
NO995852L (en) 2000-01-31
JP2002501529A (en) 2002-01-15
CN1258295A (en) 2000-06-28
HU225987B1 (en) 2008-02-28
ATE239011T1 (en) 2003-05-15
US20020198239A1 (en) 2002-12-26
MY127793A (en) 2006-12-29
EG24291A (en) 2009-01-08
HUP0001849A2 (en) 2002-05-29
UA60334C2 (en) 2003-10-15

Similar Documents

Publication Publication Date Title
CA2521391A1 (en) Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate
AUPN720295A0 (en) Apparatus for attaching objects to walls and the like
AU7731594A (en) Process for forming integral skin micorcellular structures
AU9050291A (en) Tacking agent
AU6345896A (en) Structured surface fastener
AU7292396A (en) Press-stud
AU3619095A (en) Pyrazolylmethyl-thiazolidines useful as hypoglycemic agents
AU5727296A (en) 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
USD379129S (en) Anchor blanket
AU3089589A (en) Magnesium potassium citrate
AU6629496A (en) Antiviral agent and process for preparing the same
AU6280394A (en) Ultrasonic activator
AU6176294A (en) Three-dimensional strategy game
AU7506594A (en) Engine
AU3119493A (en) Magnesium alloy
AU673401B2 (en) 6,7-dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound
AU7696394A (en) Process for the preparation of alkylglycosides
AU5611894A (en) Extended duration antacid product
AU5945096A (en) Impact-type anchor
AU6337694A (en) Acid microemulsion composition
AU7782694A (en) Acylated sulphonamides as insecticides and acaricides
AU4983693A (en) Refined magnesium material and process for producing the same
AU3093692A (en) High-strength magnesium alloy
AU1201597A (en) Fasteners
AU4437689A (en) Personal ornaments

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180525